Diabetic Peripheral Neuropathic Pain

Neurology
10
Pipeline Programs
5
Companies
11
Clinical Trials
4 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
5
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

VP
JOURNAVXApproved
suzetrigine
Vertex Pharmaceuticals
Sodium Channel Blocker [EPC]oral2025

Competitive Landscape

5 companies ranked by most advanced pipeline stage

VP
4 programs
1
3
1
SuzetriginePhase 31 trial
JOURNAVX(Suzetrigine)Phase 31 trial
SuzetriginePhase 31 trial
VX-993Phase 21 trial
Active Trials
NCT06619860Recruiting300Est. May 2026
NCT07231419Recruiting734Est. Apr 2027
NCT06696443Active Not Recruiting455Est. Jan 2027
+1 more trials
M&
Merck & Co.RAHWAY, NJ
1 program
1
Gabapentin/B-complexPhase 41 trial
Active Trials
NCT01364298CompletedEst. Jul 2012
DS
Daiichi SankyoChina - Shanghai
4 programs
2
DS-5565Phase 31 trial
MirogabalinPhase 31 trial
No DrugN/A1 trial
No DrugN/A1 trial
Active Trials
NCT06812117Recruiting720Est. Apr 2026
NCT06546202Completed1,271Est. Jul 2025
NCT02607280Completed35Est. Mar 2017
+1 more trials
Gedeon Richter
Gedeon RichterHungary - Budapest
1 program
1
RGH-896Phase 21 trial
Active Trials
NCT00838799Completed458
Biogen
BiogenCAMBRIDGE, MA
1 program
1
RTA 901Phase 21 trial
Active Trials
NCT05895552Terminated209Est. Nov 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Merck & Co.Gabapentin/B-complex
Vertex PharmaceuticalsSuzetrigine
Vertex PharmaceuticalsSuzetrigine
Vertex PharmaceuticalsSuzetrigine
Daiichi SankyoMirogabalin
Daiichi SankyoDS-5565
Vertex PharmaceuticalsVX-993
BiogenRTA 901
Gedeon RichterRGH-896
Daiichi SankyoNo Drug
Daiichi SankyoNo Drug

Clinical Trials (11)

Total enrollment: 5,675 patients across 11 trials

NCT01364298Merck & Co.Gabapentin/B-complex

Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management

Start: Apr 2011Est. completion: Jul 2012
Phase 4Completed
NCT07231419Vertex PharmaceuticalsSuzetrigine

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

Start: Nov 2025Est. completion: Apr 2027734 patients
Phase 3Recruiting
NCT06696443Vertex PharmaceuticalsSuzetrigine

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

Start: Dec 2024Est. completion: Jan 2027455 patients
Phase 3Active Not Recruiting
NCT06628908Vertex PharmaceuticalsSuzetrigine

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

Start: Oct 2024Est. completion: May 20271,100 patients
Phase 3Recruiting
NCT04094662Daiichi SankyoMirogabalin

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Start: Sep 2019Est. completion: Jan 2022393 patients
Phase 3Completed
NCT02607280Daiichi SankyoDS-5565

DS-5565 Phase III Study for Renal Impairment in Japanese Subjects

Start: Dec 2015Est. completion: Mar 201735 patients
Phase 3Completed
NCT06619860Vertex PharmaceuticalsVX-993

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Start: Oct 2024Est. completion: May 2026300 patients
Phase 2Recruiting
NCT05895552BiogenRTA 901

A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain

Start: Jul 2023Est. completion: Nov 2024209 patients
Phase 2Terminated
NCT00838799Gedeon RichterRGH-896

Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain

Start: Feb 2009458 patients
Phase 2Completed
NCT06812117Daiichi SankyoNo Drug

A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)

Start: Jan 2025Est. completion: Apr 2026720 patients
N/ARecruiting
NCT06546202Daiichi SankyoNo Drug

Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China

Start: Aug 2024Est. completion: Jul 20251,271 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
8h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
9h ago

Director of Finance

CoMind
London, UK
9h ago

Electronics Engineering Manager

CoMind
London, UK
9h ago

Director of Information Technology

Zavation Medical Products
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 5,675 patients
5 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)